

1 **Integrated patient network and genomic plasmid analysis reveal a regional,**
2 **multi-species outbreak of carbapenemase-producing Enterobacterales**
3 **carrying both *bla*_{IMP} and *mcr-9* genes**

4
5 Adhiratha Boonyasiri^{1,2*}, Ashleigh C. Myall^{1,3*}, Yu Wan^{1*}, Frances Bolt^{1,4,5}, Alice Ledda^{6,7},
6 Siddharth Mookerjee⁴, Andrea Y. Weiße^{8,9}, Jane F. Turton⁷, Hala Abbas^{1,10}, Ruta Prakapaite¹¹,
7 Akshay Sabnis¹¹, Alireza Abdolrasouli⁴, Kenny Malpartida-Cardenas^{1,12}, Luca Miglietta^{1,12},
8 Hugo Donaldson¹⁰, Mark Gilchrist^{1,4}, Katie L. Hopkins^{1,7}, Matthew J Ellington^{1,13}, Jonathan A.
9 Otter¹, Gerald Larrouy-Maumus^{1,14}, Andrew M. Edwards¹¹, Jesus Rodriguez-Manzano^{1,5,12},
10 Xavier Didelot¹⁵, Mauricio Barahona³, Alison H. Holmes^{1,4,5}, Elita Jauneikaite^{1,6#} and Frances
11 Davies^{1,4,10#}

- 12
13 1. NIHR Health Protection Research Unit in Healthcare Associated Infections and
14 Antimicrobial Resistance, Department of Infectious Disease, Imperial College London,
15 Hammersmith Hospital, London, UK.
16 2. Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
17 3. Department of Mathematics, Imperial College London, London, UK
18 4. Imperial College Healthcare NHS Trust, London, UK
19 5. Centre for Antimicrobial Optimisation, Hammersmith Hospital, Imperial College London,
20 Du Cane Road, London, UK
21 6. Department of Infectious Disease Epidemiology, School of Public Health, Imperial
22 College London, London, UK
23 7. HCAI, Fungal, AMR, AMU & Sepsis Division, UK Health Security Agency, London, UK
24 8. School of Biological Sciences, University of Edinburgh, Scotland, UK
25 9. School of Informatics, University of Edinburgh, Scotland, UK
26 10. Department of Microbiology, North West London Pathology, London, UK
27 11. MRC Centre for Molecular Bacteriology and Infection, Department of Infectious Disease,
28 Faculty of Medicine, Imperial College London, London, United Kingdom
29 12. Centre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering,
30 Faculty of Engineering, Imperial College London, UK
31 13. Reference Services Division, UK Health Security Agency, London, UK
32 14. MRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences,
33 Faculty of Natural Sciences, Imperial College London, London, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 15. School of Life Sciences and Department of Statistics, University of Warwick, UK

35

36

37 * These authors contributed equally; # these senior authors contributed equally.

38

39 **Keywords:** Carbapenem-resistant Enterobacterales, IMP carbapenemase, antimicrobial
40 resistance, horizontal gene transfer, molecular epidemiology, spatiotemporal network, patient
41 pathways

42

43 Abstract

44 The incidence of carbapenemase-producing Enterobacterales (CPE) is rising globally, yet
45 Imipenemase (IMP) carbapenemases remain relatively rare. This study describes an
46 investigation of the emergence of IMP-encoding CPE amongst diverse Enterobacterales
47 species between 2016 and 2019 in patients across a London regional hospital network.

48
49 A network analysis approach to patient pathways, using routinely collected electronic health
50 records, identified previously unrecognised contacts between patients who were IMP CPE
51 positive on screening, implying potential bacterial transmission events. Whole genome
52 sequencing of 85 Enterobacterales isolates from these patients revealed that 86% (73/85) were
53 diverse species (predominantly *Klebsiella* spp, *Enterobacter* spp, *E. coli*) and harboured an
54 IncHI2 plasmid, which carried both *bla*_{IMP} and the putative mobile colistin resistance gene *mcr*-
55 9. Detailed phylogenetic analysis identified two distinct IncHI2 plasmid lineages, A and B,
56 both of which showed significant association with patient movements between four hospital
57 sites and across medical specialities.

58
59 Combined, our patient network and plasmid analyses demonstrate an interspecies, plasmid-
60 mediated outbreak of *bla*_{IMP}CPE, which remained unidentified during standard microbiology
61 and infection control investigations. With whole genome sequencing (WGS) technologies and
62 large-data incorporation, the outbreak investigation approach proposed here provides a
63 framework for real-time identification of key factors causing pathogen spread. Analysing
64 outbreaks at the plasmid level reveals that resistance may be wider spread than suspected,
65 allowing more targetted interventions to stop the transmission of resistance within hospital
66 networks.

67 Introduction

68 Infections by carbapenemase-producing Enterobacterales (CPE) pose a substantial clinical,
69 operational, and financial challenge¹. These organisms are associated with high morbidity and
70 mortality, and therapeutic options are severely restricted^{2,3}. Carbapenemase genes are
71 frequently carried on plasmids, which can easily transfer between bacterial species. CPE
72 outbreaks involving different bacterial species are often unrecognised, as many plasmids are
73 variable in their gene content⁴ and have a broad host range⁵. The metallo- β -lactamase – (MBL)
74 Imipenemase gene (IMP)-1, was first described in *Pseudomonas aeruginosa*⁶, whilst IMP
75 genes have spread globally, outbreaks in Enterobacterales species are mostly sporadic and often
76 localised to specific geographical locations⁷⁻⁹. IMP genes are rarely isolated in the UK, but the
77 number of IMP encoding isolates within Enterobacterales species referred to UK Health
78 Security Agency (UK HSA) has been increasing^{10,11}.

79

80 Therapeutic options are particularly limited for MBL CPEs, with limited efficacy of the newer
81 beta-lactam combination agents^{2,3}. Colistin and polymyxin B remain the last-line therapeutic
82 agents in most countries, partly due to lack of access to newer agents; yet resistance is
83 increasing globally, particularly through mobilised colistin resistance (*mcr*) genes on
84 plasmids^{12,13}. Since the first discovery of *mcr-1* in 2016¹⁴, ten *mcr* genes (*mcr-1* to *mcr-10*)
85 have been described to date, presenting a substantial global healthcare challenge^{13,15}. Although
86 *mcr* genes are typically associated with phenotypic polymyxin resistance, *mcr-9*, identified in
87 2019, does not appear to confer direct colistin resistance^{7,16}. It has been detected in clinical
88 isolates co-harboured different resistance genes in Australia (with *bla*_{IMP-4}), South Africa (with
89 ESBLs), Egypt and the Netherlands (with *bla*_{VIM}) and Japan (with *bla*_{IMP-1})^{7,8,17-20}, and is
90 widespread in isolates from human, animal and environmental origins, in a wide range of
91 bacterial species^{7,21}.

92

93 Person-to-person contact is a route of transmission for many infectious diseases. Consequently,
94 understanding the patterns of these contacts, especially in healthcare settings, can offer detailed
95 insight for targeted interventions²². Contact patterns, however, become increasingly complex
96 when considering large numbers of interacting individuals over long-time spans, bacterial
97 interactions with the human host and environment, bacterial behaviour under antibiotic and
98 disinfectant pressure, and plasmids that can be shared by multiple bacterial species. Network
99 models provide flexible tools to capture such complex contact patterns, with the availability of

100 well-developed analytical toolboxes they offer robust and reproducible methodology that has
101 become widespread across disciplines²³. Network models of infectious diseases²⁴⁻²⁶ incorporate
102 both person-to-person transmission through contact networks²⁷⁻³⁰ and spatial spread through
103 networks representing physical locations and their relationships^{31,32}. So far, studies utilising
104 network models of patient contacts in combination with detailed genomic analysis of bacterial
105 isolates have demonstrated their promise through increasing the detail in outbreak
106 characterisation^{33,34}.

107

108 Here we describe the emergence of *bla*_{IMP} and *mcr-9* co-harboured by diverse Enterobacterales
109 species that have been isolated from patients across a regional network of London hospitals
110 between 2016 and 2019. We combine in-depth phylogenomic analysis of the IncHI2 plasmid
111 containing *mcr-9* and *bla*_{IMP} with a network model of patient movements to provide novel
112 insight into the spread and dissemination of *bla*_{IMP} and *mcr-9* between bacterial species and
113 patients over 3 years, with implications for how CPE clusters are identified and managed in the
114 hospital setting.

115

116

117 **Results**

118 ***Emergence of bla*_{IMP}CPE**


119 Following the introduction of enhanced CPE screening in 2015³⁵, a CPE-carrying *bla*_{IMP}
120 (*bla*_{IMP}CPE) was first observed in our hospital group in June 2016 from a routine rectal
121 screening sample. From November 2016, increasing numbers of *bla*_{IMP}CPE isolates were
122 identified across diverse Enterobacterales species at three of the acute hospital sites
123 (representing 64% of all inpatient beds at our institution) (**Figure 1a**), and simultaneously at
124 two other external hospitals in the regional network, all served by the same microbiology
125 diagnostics laboratory, and closely connected by regular inter-hospital patient transfers. The
126 highest incidence of *bla*_{IMP}CPE cases occurred in January and April 2019 (**Figure 1b**). In total,
127 *bla*_{IMP}CPE were isolated from screening or clinical samples from 116 patients who were
128 admitted to our hospital group up until the end of November 2019, when new cases rapidly
129 dropped, despite no targeted changes in infection control interventions. However, only two
130 clusters of cases, (totalling 5 out of 116 cases), fitted the real-time infection control outbreak
131 definition, i.e. two or more cases of the same bacterial species with the same resistance
132 mechanism overlapping in time and space. Pulsed Field Gel Electrophoresis (PFGE) typing

133 performed at the public health laboratories for those 5 cases had confirmed similarity,
134 suggesting cross transmission events had occurred.

135 To reveal the operational burden of *bla*_{IMP}CPE, the daily number of occupied beds was
136 computed for all colonised patients. The analysis revealed a continuous burden of patients
137 colonised with *bla*_{IMP}CPE which was far higher than expected from the new case incidence,
138 particularly for those colonised with *Enterobacter* species (**Figure 1a,b**), with 424 total
139 inpatient bed days per month at the peak (March 2019), across the hospital network (**Figure**
140 **1c**).

141
142 **Figure 1: Characteristics of confirmed *bla*_{IMP}CPE patient cases and distribution of CPE**
143 **species. (A)** Total number of days patients (rows labelled by CPE isolate identifier) were
144 present in a hospital ward before confirmed to be colonised/infected with *bla*_{IMP}CPE (*in-*
145 *hospital infectious period*) and infection prevention and control measures were taken.
146 Additionally, patients with known carriage of *bla*_{IMP}CPE but without sequenced isolates are
147 shown as unlabelled rows. Patients with paired isolates (IMP 22/24, IMP 25/33, IMP 96/97,
148 IMP 100/101) are on adjacent rows. **(B)** Monthly total number of confirmed *bla*_{IMP}CPE isolates
149 detected in patients during the study period from 2016 to 2019. **(C)** Weekly cumulative number
150 of bed days of patients with confirmed carriage of *bla*_{IMP}CPE before they identified as
151 colonised with *bla*_{IMP}CPE over their infectious in-hospital period. Colours in each of the panels
152 indicate the genus of CPE identified in the study.

153



154

155 **Contact network of *bla*_{IMP}CPE patients**

156 A detailed patient contact network for all 116 *bla*_{IMP}CPE colonised/infected patients who were
157 identified in our hospital group, including data from their admissions at the other regional
158 hospitals, confirmed that 77/116 (66%) patients were in contact with at least one other
159 *bla*_{IMP}CPE colonised/infected patient (**Figure 2**). The analysis showed that the median number
160 of contacts was two per patient, however, contact numbers displayed substantial variation. For
161 example, one patient (Case 85, cluster 1.5) had 10 contacts with 9 other patients which linked
162 them to 8% of all cases (**Table S1**) and therefore identified the patient as a potential ‘super-
163 spreader’ in the outbreak.

164

165 Across all *bla*_{IMP}CPE patient contact pairs, 57/96 (59%) pairs differed in bacterial species (8
166 species identified carrying *bla*_{IMP}), explaining why these contacts were not identified as
167 outbreak-related using the clinical infection control outbreak definition, which was reliant on
168 the same bacterial species rather than resistance mechanism. The network of patient contacts
169 split patients into 12 separate clusters, with interactions occurring across hospitals, as patients
170 were transferred between wards and sites (**Figure 2**). The largest cluster (Cluster 1) contained
171 45 patients and was partitioned into a further seven subclusters, labelled 1.1 to 1.7, that
172 comprised 13, 12, 2, 6, 5, 5 and 2 patients, respectively (**Figure 2**). The analysis of *bla*_{IMP}CPE
173 patient contacts, at regional, individual hospital and ward level, suggested that different species

174 of *bla*_{IMP}CPE were involved intransmission events (**Figure 2**). This multi-species involvement
175 in the ongoing outbreak prompted genomic analysis of the available *bla*_{IMP}CPE isolates.

176

177 **Figure 2. Patient contact network of interactions among *bla*_{IMP}CPE positive patients.**

178 Each node of the network represents a patient (coloured according to *bla*_{IMP}CPE isolate

179 species) and each edge represents a contact between two patients. Edges represent recorded

180 contacts between confirmed *bla*_{IMP}CPE cases (patients present on the same ward on the same

181 day according to their electronic health records). The patient contact network identified 12

182 distinct clusters (each shaded in a different colour) based on disconnected components of


183 patient contact. Cluster 1, the largest cluster consisting of 45 patients, was further partitioned

184 into 7 subclusters using community detection with edges weighted by duration of contact (see

185 Supplementary methods – Community detection). Six patient contacts re-occurred over

186 different wards, indicated by additional edges connecting the same patients.

187



188

189

190 **Genomic and phenotypic characterisation of *bla*_{IMP}CPE isolates**

191 A total of 85 bacterial isolates from 82/116 *bla*_{IMP}CPE colonised patients were sequenced for
192 genomic analysis (**Table S2**). The *bla*_{IMP} gene was detected in 13 different bacterial species,

193 most commonly in members of the *Enterobacter cloacae* complex species (55/85), *K.*

194 *pneumoniae* (16/85) and *E. coli* (10/85) (**Table S2**). Most patients harbour only one *bla*_{IMP}


195 encoding species, but there were four patients who were colonised with two different bacterial
 196 species that carried *bla*_{IMP} (Table S2).

197

198 Genomic analysis identified that two alleles, *bla*_{IMP-1} (75/85) and *bla*_{IMP-4} (10/85), co-occurred
 199 with two groups of plasmids: IncHI2 plasmid was identified in 72/85 isolates and IncN3 in
 200 11/85 (Figure 3). One isolate of *K. aerogenes* (IMP79) carried both plasmids, and two isolates
 201 (IMP47, IMP76) carried a different plasmid co-occurring with *bla*_{IMP-1}. As expected, all
 202 *bla*_{IMP}CPE isolates had carried multiple β-lactam resistance genes in addition to other
 203 antimicrobial resistance genes (Table S3), though only one isolate (IMP89) had another
 204 carbapenem resistance gene, *bla*_{OXA-48} (Table S3).

205

206 **Figure 3. Phylogenetic tree of 85 Enterobacterales genomes in this study.** A neighbour-
 207 joining phylogenetic tree of 85 Enterobacterales genomes was constructed using whole-
 208 genome FastANI distances. The colour at the end of each branch indicates the species identity
 209 for that isolate. The rings are as follows: the innermost ring indicates the type of plasmid
 210 detected; the middle ring indicates the allelic variant of the *bla*_{IMP} gene detected, and the outer
 211 ring indicates the presence or absence of the *mcr-9* gene. NF = not found. The scale bar
 212 indicates the average nucleotide distance (in percent) per site.



213

214

215 The multi-species distribution of the 72 IncHI2 plasmids among contact network linked
216 patients, was highly suggestive of plasmid mobility. The *mcr-9* gene was detected in 81%
217 (69/85) of all *bla*_{IMP}CPE isolates, all of which harboured the IncHI2 plasmid (94% 69/72 of
218 IncHI2 plasmid carrying isolates; none of IncN3 plasmids had *mcr-9*). The *mcr-9* specific
219 LAMP assay confirmed the presence of *mcr-9* with 100% concordance (**Table S4**) as
220 previously reported³⁶. MALDIxin (which detects modifications to the lipid A of the
221 lipopolysaccharide as mediated by *mcr1-5* and *mcr-8*³⁷) did not detect any Lipid A
222 modifications attributable to the *mcr-9* gene in this study. Altogether, 12/84 isolates tested (all
223 *Enterobacter* species) were resistant to colistin with MICs > 2 µg/ml (range 4 to >64 µg/ml)
224 (**Table S4**), and 5 isolates demonstrated a skipped-well phenomenon³⁸ suggestive of colistin
225 heteroresistance. However, determining the contribution of *mcr-9* or other mechanisms of
226 resistance to this was beyond the scope of this study, and will be the subject of future
227 investigations.

228


229 ***Population structure of IncHI2 plasmids***

230 Phylogenetic analysis of the 72 IncHI2 plasmids (where reads were mapped to complete
231 genomic sequence of plasmid pKA_P10 (NZ_CP044215.1)) identified two major lineages (A
232 and B) and four sublineages (A.1, A.2, B.1 and B.2, **Figure 4**). While all the isolates were
233 carrying multiple antimicrobial resistance (AMR) genes and multiple plasmids, only plasmids
234 of the B.1 lineage carried *bla*_{IMP-4} and were present in isolates that also exclusively saw co-
235 occurrence of *tet*(D), *qnrB2*, *bla*_{OXA-1} and *mph*(A) (**Figure 4**). Comparison of 233 plasmid core-
236 genome single-nucleotide polymorphisms (cgSNPs) showed some congruency of cgSNPs with
237 the plasmid sequences (**Figure S1**). Furthermore, this analysis grouped the IncHI2 plasmids
238 into 15 polytomic clades (with identical SNP profiles), of which 12 showed identical cgSNPs
239 after masking recombination regions (**Table S5** and **Figure S2**).

240

241 **Figure 4. Dated phylogenetic tree showing the relationship between 72 IncHI2 plasmids**
242 **identified in CPE isolates with *bla*_{IMP}.** The complete genome of IncHI2 plasmid pKA_P10
243 was used as the reference for variant calling. The tree was generated and rooted using
244 BactDating. Branch colours denote major plasmid lineages, which are supported by bootstrap
245 values of 100. At the tips of the tree, circles represent plasmids from routine rectal screening
246 samples, and squares represent plasmids from clinical samples. Colours of the tip symbols
247 indicate species. Lineage identifiers are labelled above lineage-specific root branches. The

248 column panel to the right of the phylogenetic tree indicates presence-absence of mobile
 249 antimicrobial resistance genes and plasmid replicons. NA: information was not available.
 250
 251



252
 253
 254 The root of the plasmid tree was dated in 1949 (95% CI: 1927-1971), with the most recent
 255 common ancestors of lineages A and B dated in 1965 (95% CI: 1943–1988) and 1967 (95%
 256 CI: 1945–1988), respectively (**Figure S3**). These estimates suggest that not only IncHI2
 257 plasmids have been circulating amongst *Enterobacteriales* for many decades, but also that they
 258 have undergone extensive evolution in the antibiotic era.

260 *Plasmid lineages and patient cluster comparisons*


261 To investigate if the identified IncHI2 plasmid lineages A and B were responsible for the
 262 emergence of *bla*_{IMP}CPE in our hospital network, plasmid genomic data was overlaid onto the

263 patient contact network (**Figure 5, Figure S4**). IncHI2 plasmid lineage A (3/72 IncHI2
264 plasmids) was exclusively linked to patients in cluster 5 (**Figure 5**), with contacts confined to
265 the same hospital site, highly suggestive of a patient-to-patient or common-source transmission
266 event. The predominant IncHI2 plasmid clade B, representing 69/72 plasmids sequenced and
267 60% of all cases identified in the study, was distributed widely across the hospital network,
268 dominated Cluster 1 of patient contact clusters, and showed particularly strong association with
269 contacts at hospital site 3 (**Figure 5**). The IncN3 plasmid (9.5% of overall cases) displayed
270 strong association with patients in network Cluster 9, with contacts occurring at three different
271 hospitals (hospitals 1, 2 and 3) (**Figure 5**). Although 3 of the IncN3 cases in cluster 9 had been
272 identified as an outbreak (Cases 80, 81 and 82) at the time of initial isolate identification, 5
273 other linked cases have now been revealed by this combined network and plasmid analysis,
274 that were previously missed. Similarly, Cases 67 and 71 (Cluster 1.2), identified real-time as
275 related cases, are revealed by this combined analysis to be linked to multiple (n=34) other cases
276 across clusters 1.1, 1.2, 1.3 and 1.4, with the IncHI2 plasmid lineage B.2.

277

278 **Figure 5. Patient contact network of interactions among patients focussed on specific**
279 **locations of contact and plasmid information.** Each node represents a patient, edges
280 represent recorded ward contacts between confirmed *bla*_{IMP}CPE cases. The edges are coloured
281 according to the hospital site (site 1-4) and the width of the edge is proportional to the duration
282 of the contact. Cluster nodes are coloured according to the lineage of the IncHI2 plasmid
283 identified in whole genome sequenced *bla*_{IMP}CPE isolates; patients with isolates lacking the
284 IncHI2 plasmid are coloured in white; patients with no whole genome sequenced *bla*_{IMP}CPE
285 isolates are displayed as labels without a circle. The presence of an IncN3 plasmid in the
286 *bla*_{IMP}CPE isolates is denoted by dark-grey borders surrounding the nodes. Contact network
287 clusters are highlighted with individual colour shading as in Figure 4.

288



289

290

291 Bacterial sequence data was missing from some cases that could have clarified links between
 292 and within plasmid lineages A and B, as suggested by the contact network analysis. Similarly,
 293 data was not available for potentially linked cases identified at other regional sites but not
 294 transferred to our hospital network. Despite missing hospital network data, clear associations
 295 between plasmid clades and patient pathway network clusters are evident, supporting the
 296 hypothesis of plasmid spread throughout the course of this outbreak, particularly at hospital 3.
 297 When reviewing the cumulative burden of the plasmid clades over time, it becomes apparent
 298 that most of the the cumulative bed days of patients shown in Figure 1 are due to patients
 299 colonised with clade B2 (**Figure S5**).

300

301 *Spatial and temporal analysis*


302 Having identified four plasmid lineages among the 72 *bla*_{IMP}-CPE IncHI2 plasmids, a network
 303 was constructed capturing the structure of patient transfers among hospital wards and used to
 304 investigate the spatial distribution of the four major plasmid lineages (**Figure 6**). The smaller
 305 plasmid lineages A.1 and A.2 were present in only two and one patients, respectively, and
 306 hence, were locally constrained by a smaller set of patient movements. Plasmid lineage A.1
 307 was localised within hospital 3 renal services and had no recorded patient inter-hospital

308 movement. Plasmid lineage A.2 was localised to a single patient movement within hospital 4,
309 then an inter-hospital movement to hospital 2. Patients with isolates in plasmid lineage B.1
310 were recorded on wards from hospital sites 1, 2, 3 and 5. However, inter-hospital transfers of
311 these patients were only recorded between hospitals 2 and 5, and hospitals 3 and 5. It is thus
312 likely that some transmission of plasmid lineages B.1 was missed, either through patients who
313 were not detected on screening, or these were patients whose isolates were not available for
314 sequencing. Plasmid lineage B.2 was spatially more distributed with recorded multiple bi-
315 directional inter-hospital transfers among hospital sites 1, 2, 3 and 5. Looking at the association
316 between plasmid lineage clusters and ward/specialties over the study period the most common
317 associations across all specialities were critical care and renal services (**Table S6**). The only
318 exception was general internal medicine and general surgery predominated in plasmid lineage
319 B.1 at hospital site 5, which has more general wards and less specialist services than the other
320 hospital sites in the network. Despite the predominance of cases being identified in specialties
321 with high risk for invasive disease, only 4 clinical infections were identified during the study,
322 and no blood stream infections (**Table S2**)

323

324 **Figure 6. Spatial analysis representing the pathways of patient transfers among wards**
325 **and hospitals.** Movement of patients carrying *bla*_{IMP}CPE are represented by arrows between
326 wards (nodes) and the five hospitals (dotted ovals). For hospital site 5, only hospital-level data
327 was available, therefore, only intra-hospital movement is shown. Repeated transfers of patients
328 between wards are aggregated into edges with proportionally greater edge width. Plasmid
329 clusters, based on plasmid lineage (A.1, A.2, B.1 and B.2) are coloured accordingly. For
330 patients with multiple CPE isolates, transfers are duplicated to match each isolate uniquely in
331 the visualisation.

332



333

334

335 Although the first case was identified in 2016 (IMP 51/Case 91), a temporal network analysis
 336 indicated it played only a minor role in onward transmission, due to the small number of
 337 reachable patients over time (**Figure S6**). This may suggest that previous/subsequent patients
 338 were not identified or point to the existence of an environmental reservoir. Considering the
 339 timing and ordering of all contacts, IMP79 could have seeded up to 27 subsequent cases
 340 (restricted to those in Cluster 1 in **Figure 2**), either directly or indirectly, via possible
 341 transmission routes. The patient carried the isolate that co-harboured both IncN3 and IncHI2
 342 plasmids, potentially suggesting multiple transmission opportunities to, as well as, from, this
 343 patient. There were 14 patients (15 isolates) from the 72 isolates carrying an IncHI2 plasmid,
 344 which had a proportionately larger number of reachable time-ordered contacts, suggesting that
 345 these patients may also have contributed substantially to transmission (**Figure S6**).

346

347 These integrated geno-spatio-temporal representations show that the spread of plasmids
 348 containing *bla*_{IMP} followed patient movements for specialty care around the region, with
 349 possibly multiple introductions and re-introductions of the plasmid at different points during
 350 the patient journeys, and multiple chances for cross transmission events to have occurred.

351

352

353 Discussion

354 Following the detection of a new mechanism of resistance, investigation of its origin and mode
355 of transmission is challenging, especially in healthcare settings where investigations usually
356 focus on single species cross transmissions. With confounding factors such as multiple
357 bacterial species and spread over different hospital locations, new methods to investigate
358 potential outbreaks are much needed. The incorporation of plasmid genomics and patient
359 networks into our analysis changed the way the emergence of *bla*_{IMP}CPE was visualised and
360 produced a clearer understanding of the high-risk ward locations and pathways for potential
361 cross transmission in our regional healthcare system. As patients were found to follow common
362 routes, with regular re-encounters, this information can provide dynamic risk assessments to
363 be introduced along those pathways, to prevent future cross transmission events of any
364 healthcare-associated pathogen from occurring³⁹. Detailed genomic analysis of plasmids
365 enhanced our understanding of the relatedness of different patient isolates to the network
366 analysis. It moreover revealed concerning information about unsuspected resistance
367 mechanisms, with potential for antibiotic treatment failures that were missed on conventional
368 laboratory susceptibility testing. In this study, we characterized IncHI2 plasmids as the main
369 vehicle in horizontal transfer of the metallo- β -lactamase gene *bla*_{IMP}. A dated phylogeny of the
370 IncHI2 plasmid carrying *bla*_{IMP}, indicated that this plasmid underwent a clonal expansion
371 around 2008, about 8 years before the onset of the outbreak described in our study. IncHI2
372 plasmids are common, large plasmids with a wide host range, that has been reported globally¹⁹,
373 and more recently have been reported to be associated with colistin resistance genes *mcr*-1 and
374 *mcr*-3^{40,41}. Although in our study we detected *mcr*-9 in 81% of the isolates tested, we did not
375 find evidence of phenotypic expression of this gene, in line with previous observations^{7,42}. We
376 identified the predominant IncHI2 plasmid in multiple different bacterial species across linked
377 patients, highlighting the need for integration of genomics into routine clinical practice.
378 Although this study focussed on the emergence of the *bla*_{IMP} carbapenemase gene in our
379 hospital network, it supports the concept that plasmid analysis across different resistance
380 mechanisms as well as among different species should be the standard for investigations in the
381 future. The small number of clinical infections from this outbreak in comparison to other CPE
382 outbreaks from our hospital network⁴³ and other reports of *bla*_{IMP} CPE^{7,19} is noteworthy, and
383 poses questions about the wider importance of this plasmid and the resistance mechanisms
384 revealed in this study. This observation reinforces the argument that screening for silent
385 carriage of CPE in hospitals is key to preventing spread⁴⁴⁻⁴⁶, and cautious antimicrobial

386 stewardship is essential to prevent expression of hidden resistance mechanisms⁴⁷.The
387 association of IMP carbapenemases and drainage^{48,49}, leads to speculation that the acquisition
388 of this plasmid may provide an environmental survival advantage, enhancing the potential for
389 spread between human hosts through a poorly maintained plumbing environment^{50,51}.

390

391 We acknowledge some limitations of our study. Firstly, long-read data was available only for
392 two isolates, pKA_P10 and pEB_P9 (NZ_CP043767.1)¹⁰, and though both were tested as
393 references, assumptions had to be made for in-depth genomic analysis of our plasmids. As a
394 result, our plasmid tree may omit some similarities and differences between identified IncHI2
395 plasmids. Secondly, full pathway data across the hospital during the three years of the outbreak
396 was only available for identified positive cases, not for all patients. It was therefore not possible
397 to fully establish potential missed cases flagging as close contacts but with potential for missed
398 screening or false negative results. Full pathway movement data for all positive cases identified
399 within our hospital network was available, yet neither pathway details nor genomic data were
400 available for other *bla*_{IMP}CPE-positive cases identified in the two other regional hospitals who
401 did not visit our institution, thus reducing the understanding in our analysis. Interactions at
402 other potential hospital locations such as interventional imaging or endoscopy were not
403 examined in this study, nor was environmental sampling performed, which could inform future
404 studies on modes of transmission. Nevertheless, this study highlights a previously unidentified
405 extent of transmission and thus provides valuable new insights into the spread of an emerging
406 resistance mechanism. Moreover, our novel multi-layered methodology, incorporating plasmid
407 phylogeny with contact network analysis, provides invaluable tools for outbreak investigation
408 that can be generalised to a wide range of scenarios.

409

410

411 **Materials and Methods**

412 *Clinical Setting*

413 This study was carried out using data from a regional network of London hospitals, comprising
414 of 7 hospital sites with a total of 2000 inpatient beds, with managerial responsibility assigned
415 to 2 different NHS Trusts. Cases of colonisation/infection with *bla*_{IMP}CPE were identified at 3
416 hospital sites from one NHS trust (referred to as our Institution in the results) and 2 hospital
417 sites from the other. All hospitals in the network are served by the same centralised

418 microbiology laboratory and patients are frequently transferred between hospitals in the
419 regional network for specialist investigations and treatment.

420

421 *Sampling, microbiology, antimicrobial susceptibility testing and detection of mcr-9*

422 *bla*_{IMP}-encoding Enterobacterales isolates were cultured from rectal screens or clinical samples
423 as part of routine diagnostic testing between June 2016 and November 2019. Rectal screens
424 were cultured on chromogenic media (Colorex™ mSuperCARBA™, E&O Laboratories, UK),
425 and species identification was performed using Biotyper MALDI-TOF MS (Bruker Daltonics,
426 Germany) according to the manufacturer's protocol. Antimicrobial susceptibility testing was
427 performed according to EUCAST guidelines⁵², colistin susceptibility testing was performed
428 by broth microdilution on all viable isolates according to manufacturer's instructions
429 (MICRONAUT, BioConnections, UK)⁵². The identification and detection of carbapenemase
430 genes was by PCR (Xpert® Carba-R, Cepheid Inc, USA). After February 2018, all isolates were
431 tested using the RESIST 3 O.K.N. K.SeT (Coris BioConcept, Belgium), and negative isolates
432 had the carbapenem inactivation method (CIM) performed, and CIM positive isolates then had
433 PCR (Xpert® Carba-R, Cepheid Inc, USA) performed as previously described³⁵. *bla*_{IMP} positive
434 isolates with suspected links were sent to UK Health Security Agency (UK HSA) reference
435 laboratories for typing by Variable Number Tandem Repeat VNTR (*Klebsiella* sp.) or Pulsed
436 Field Gel Electrophoresis PFGE (all other species).

437 Loop-mediated isothermal amplification (LAMP) was used to examine the prevalence of *mcr-*
438 *9* amongst *bla*_{IMP}CPE isolates as described previously⁵³. MALDIxin testing was conducted to
439 confirm phenotypic colistin resistance, as previously described on isolates IMP 1-58 only³⁷.

440

441 *Whole-genome sequencing*

442 Bacterial isolates were grown on Columbia Blood Agar (Oxoid Ltd, UK), incubated aerobically
443 at 37°C overnight before DNA extraction. Genomic DNA was extracted using GenElute™
444 Bacterial Genomic DNA Kit (Sigma-Aldrich, USA) following manufacturer instructions.
445 Multiplexed DNA libraries were generated with Nextera XT (Illumina, USA) and were
446 sequenced for a minimum of 100-fold average coverage on Illumina HiSeq 4000 systems under
447 a 150-bp paired-end layout. Seven isolates (IMP09/CB_P14_L5_12.18,
448 IMP29/KP_P12_L5_11.18, IMP33/EB_P9_L5_03.19, IMP40/EB_P8_L5_01.19,
449 IMP41/KQ_P11_L5_04.19, IMP42/KA_P10_L5_03.19, IMP45/ EB_P13_L5_04.19) were
450 also sent to UK HSA for MinION (Oxford Nanopore, UK) long-read sequencing¹⁰.

451

452 *Sequence data processing and analyses*

453 Short-read sequence reads were quality assessed using FastQC v0.11.6⁵⁴. Raw reads were
454 trimmed using Trimmomatic v0.39⁵⁵ and were *de novo* assembled using SPAdes v3.11⁵⁶ and
455 annotated with Prokka⁵⁷. Species identification was confirmed with KmerFinder 3.2⁵⁸.
456 Multilocus sequence typing (MLST) was performed with the MLST v1.8 online server⁵⁹ using
457 the Achtman MLST scheme for *E. coli* curated on PubMLST and Enterobase⁶⁰ and the Pasteur
458 MLST scheme for other *Enterobacterales* isolates. AMR genes, and plasmid typing (**Table S7**)
459 were done using ResFinder v3.2⁶¹, and PlasmidFinder v2.1⁶², respectively. A neighbour-
460 joining tree of CPE isolates used in this study was generated from assemblies using FastANI
461 v1.3 based on whole-genome average nucleotide identities⁶³.

462

463 *Phylogenetic analysis of IncHI2 plasmids*

464 A reference complete genome of IncHI2 plasmids was selected from three candidates:
465 pKA_P10 (NZ_CP044215.1; 334 kbp) from *Klebsiella aerogenes*, pEB_P9 (NZ_CP043767.1;
466 331 kbp) from *Enterobacter hormaechei* isolate¹⁰ and R478 (NC_005211.1; 275 kbp)
467 identified in *Serratia marcescens*⁶⁴. The selection aimed to maximise: (i) overall coverage of
468 each reference genome by reads, (ii) the number of plasmid core-genome SNPs identified from
469 the read alignment, and (iii) bootstrap values supporting major lineages in the plasmid
470 phylogenetic tree reconstructed using the same approach based on each reference. Eventually,
471 plasmid pKA_P10 was determined as the reference for the rest of analysis (**Figures S7**).

472

473 Repetitive regions ($\geq 90\%$ nucleotide identity) in the reference plasmid genome were identified
474 using NUCmer of MUMer v3.1⁶⁵. Processed short reads of 73 IMP isolates harbouring IncHI2
475 plasmids were further filtered for a minimum length of 50 bp using Trimmomatic for improving
476 mapping specificity, given estimated read depths >100 fold per bacterial genome before and
477 after the filtering. Filtered reads were mapped to the reference pKA_P10 using Snippy
478 (github.com/tseemann/snippy) with parameters set to as follows: mapping quality $\geq Q60$, base
479 quality $\geq Q20$, base coverage ≥ 10 folds, and variant-call quality $\geq Q100$. Plasmid pIMP06 was
480 excluded from further steps as its reads covered only 27% of the reference genome. Core-
481 genome SNPs (cgSNPs, sites presented in all genomes) outside of repetitive regions were
482 identified and a whole-sequence alignment of remaining 72 plasmids against the reference was
483 generated using Snippy. A neighbour-joining tree were generated from recombination-free
484 cgSNPs using pairwise SNP counts as distance metrics (namely, SNP distances) (**Figure S8**).

485

486 Maximum-likelihood phylogenetic reconstruction from the whole-genome plasmid alignment
487 (which includes invariant sites, gaps, and masked regions) was performed using IQ-Tree
488 v1.6.12⁶⁶, with the best-fit model “HKY+F+R2” (determined through extended model
489 selection and full-tree search implemented in IQ-Tree), 10 independent runs (for tree selection),
490 and 500 bootstrap replicates (for branch supports). The resulting unrooted tree was corrected
491 for recombination using ClonalFrameML ⁶⁷ with its default parameters and the whole-genome
492 alignment of plasmids. Major plasmid lineages were identified from topology of the corrected
493 tree. Detected recombination regions and reconstructed ancestral sequences were drawn against
494 the corrected tree using the script cfml_results.R from ClonalFrameML. Sample information
495 and AMR gene content of IMP isolates harbouring these plasmids were drawn against the
496 plasmid tree using iTOL v5⁶⁸. The dating of internal nodes of the plasmid tree was inferred by
497 BactDating using the mixed-Gamma model, root-finding algorithm, 5×10^4 random walks of
498 Markov Chain Monte Carlo (MCMC), and accounting for recombination identified by
499 ClonalFrameML. To evaluate the robustness of tree reconstruction, a cgSNP tree was generated
500 by IQ-Tree (best-fit model: “TIM3e+ASC”; other parameters were the same as reconstructing
501 the whole-genome tree) and corrected for recombination using ClonalFrameML (with default
502 parameters). Tree comparisons (**Figures S9–S12**) were performed in R v3.6.3 with function
503 tanglegram in package dendextend⁶⁹.

504

505 *Patient contact network analysis*

506 Ward locations and timings were extracted from the Electronic Health Record (EHR) data for
507 *bla*_{IMP}CPE positive patients to establish patient movement history. Movement to other
508 locations for procedures during an inpatient episode, such as endoscopy, interventional
509 radiology or operating theatres, was not examined. To reveal potential transmission events
510 structure, a patient contact network was constructed from patient movement history, which
511 included information on when and where patients were on the same ward (for more details
512 please see Suppl. Methods). Time aggregated patient contacts were subsequently clustered to
513 reveal groups of patients more closely linked together using the Walktrap community detection
514 algorithm⁷⁰. In this framework, contacts were also weighted by the duration of time spent
515 together across their hospital episode, capturing that the probability of transmission increases
516 with the amount of time two patients spend together⁷¹. Moreover, a temporal analysis of patient
517 interactions was performed over the time ordered sequence of contacts between patients⁷² and
518 used to assess patient roles and position in transmission (for more details please see Suppl.
519 Methods).

520

521 For insights into the spatial distribution of *bla*_{IMP}CPE, a spatial network of ward/hospital
522 network, connected by the same *bla*_{IMP}CPE patient movement was generated. From this spatial
523 network, the following was calculated: total number of days patient has spent on each ward
524 over the time before they were known to be colonised with *bla*_{IMP}CPE and infection prevention
525 and control measures were taken (their infectious in-hospital period); network structure to
526 determine ward/hospital spread of *bla*_{IMP}CPE; highly visited wards from patients of each
527 specific genomic sub-cluster were also determined (using PageRank^{73,74}) and contrasted for
528 evidence of genomic localisation to hospital spaces. All network analysis and visualisation was
529 completed in Python, R, and Cytoscape⁷⁵.

530

531 *Data availability*

532 Illumina reads and draft genome assemblies of 85 isolates were deposited in European
533 Nucleotide Archive (ENA) under the BioProject accession PRJEB38818.

534

535 *Ethics*

536 This study was carried out in accordance with ethics reference 21/LO/0170 (279677), protocol
537 21HH6538 Investigation of epidemiological and pathogenic factors associated with infectious
538 diseases.

539

540

541

542 **Acknowledgements**

543 We thank the staff of the diagnostic microbiology laboratory of North West London Pathology,
544 for isolate collection and storage. We would also like to acknowledge the support of the
545 Imperial College Healthcare Trust NIHR Biomedical Research Centre (BRC). The
546 Imperial BRC Genomics Facility has provided resources and support that have contributed to
547 the research results reported within this paper. The Imperial BRC Genomics Facility is
548 supported by NIHR funding to the Imperial Biomedical Research Centre.

549

550 **Funding**

551 This work has been funded in part by faculty of medicine, Siriraj hospital, Mahidol university,
552 Thailand (awarded to AB) and Medical Research Council Clinical Academic Research
553 Fellowship scheme (awarded to FD, grant number MR/T005254/1).

554 AM is funded in part by a scholarship from the Medical Research Foundation National PhD
555 Training Programme in Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO),
556 the EPSRC Centre for Mathematics of Precision Healthcare (EP/N014529/)and through
557 an National Institute for Health Research Senior Research Investigator Award. AM and MB
558 acknowledge funding from EPSRC grant EP/N014529/1 to MB, supporting the EPSRC Centre
559 for Mathematics of Precision Healthcare. AS is funded by a PhD studentship from the Medical
560 Research Council Doctoral Training Award to Imperial College London (MR/N014103/1).
561 AME acknowledges support from the National Institute for Health Research (NIHR) Imperial
562 Biomedical Research Centre (BRC). EJ is an Imperial College Research Fellow, funded by
563 Rosetrees Trust and the Stoneygate Trust (M683). HA was supported by the Imperial Health
564 Charity. XD is supported by the NIHR Health Protection Research Unit in Genomics and
565 Enabling Data. AL acknowledges funding from the National Institute for Health Research
566 Health Protection Research Unit (NIHR HPRU) in Modelling Methodology at Imperial
567 College London (grant HPRU-2012–10080) and the National Institute for Health Research
568 (NIHR) Health Protection Research Unit in Healthcare Associated Infections and
569 Antimicrobial Resistance at University of Oxford (NIHR200915) in partnership with UK
570 Health Security Agency. AH is a National Institute for Health Research (NIHR) Senior
571 Investigator. AH, FD, EJ, AB, YW, ME are affiliated with the National Institute for Health
572 Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections
573 and Antimicrobial Resistance at Imperial College London in partnership with the UK Health
574 Security Agency (previously PHE), in collaboration with, Imperial Healthcare Partners,
575 University of Cambridge and University of Warwick. This report is independent research
576 funded by the National Institute for Health Research. The views expressed in this publication
577 are those of the author(s) and not necessarily those of the NHS, the National Institute for Health
578 Research, the Department of Health and Social Care or the UK Health Security Agency.

579

580 **Transparency declarations**

581 JT holds some shares in Oxford Nanopore Technologies. All other authors have nothing to
582 declare.

583

584 **Author contributions**

585 Conceptualization: FD, EJ, AH, MB, FB, XD, ME. Data curation: YW, BA, EJ, AM, FD, SM,
586 AW, ME. Formal analysis: AB, AM, YW, FB, FD, EJ, AW, MB, AH, ME. Funding
587 acquisition: AB, FD, AH, ME. Investigation: AB, YW, AM, HA, RP, AL, AA, JT, LM, KM-

588 C, AS, GL-M, JR-M. Methodology: FD, AM, AW, SM, YW, EJ, BA, XD, MB, JO, KH, ME,
589 JT, MG. Project administration: FB, AH, FD, EJ. Resources: FD, AH, AE, HD, KH,
590 JT. Supervision: FD, EJ, AH, MB. Validation: KH, JT, ME, HD, AW, SM. Visualization: AB,
591 AM, YW, EJ, FD. Writing – original draft and further drafts: AB, AM, YW, EJ, FD, FB.
592 Writing – review & editing: All authors.

593

594

595 References

- 596 1 Otter, J. A. *et al.* Counting the cost of an outbreak of carbapenemase-producing
597 Enterobacteriaceae: an economic evaluation from a hospital perspective. *Clinical*
598 *microbiology and infection : the official publication of the European Society of Clinical*
599 *Microbiology and Infectious Diseases* **23**, 188-196, doi:10.1016/j.cmi.2016.10.005 (2017).
- 600 2 Doi, Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
601 *Clinical Infectious Diseases* **69**, S565-S575, doi:10.1093/cid/ciz830 (2019).
- 602 3 Pranita D. Tamma, S. L. A., Robert A. Bonomo, Amy J. Mathers, David van Duin, Cornelius J.
603 Clancy. *Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance:*
604 *Gram-Negative Bacterial Infections*, <[https://www.idsociety.org/practice-guideline/amr-](https://www.idsociety.org/practice-guideline/amr-guidance/)
605 [guidance/](https://www.idsociety.org/practice-guideline/amr-guidance/)> (2020).
- 606 4 Branger, C. *et al.* Extended-spectrum β -lactamase-encoding genes are spreading on a wide
607 range of Escherichia coli plasmids existing prior to the use of third-generation cephalosporins.
608 *Microbial genomics* **4**, doi:10.1099/mgen.0.000203 (2018).
- 609 5 Li, X. *et al.* Diversification of broad host range plasmids correlates with the presence of
610 antibiotic resistance genes. *FEMS microbiology ecology* **92**, doi:10.1093/femsec/fiv151 (2016).
- 611 6 Walsh, T. R., Toleman, M. A., Poirel, L. & Nordmann, P. Metallo-beta-lactamases: the quiet
612 before the storm? *Clinical microbiology reviews* **18**, 306-325, doi:10.1128/cmr.18.2.306-
613 325.2005 (2005).
- 614 7 Kananizadeh, P. *et al.* Emergence of carbapenem-resistant and colistin-susceptible
615 Enterobacter cloacae complex co-harboring blaIMP-1 and mcr-9 in Japan.
- 616 8 Roberts, L. W. *et al.* Genomic analysis of carbapenemase-producing Enterobacteriaceae in
617 Queensland reveals widespread transmission of bla IMP-4 on an IncHI2 plasmid. *Microbial*
618 *genomics*, doi:10.1099/mgen.0.000321 (2019).
- 619 9 Matsumura, Y. *et al.* Global Molecular Epidemiology of IMP-Producing Enterobacteriaceae.
620 *Antimicrobial agents and chemotherapy* **61**, doi:10.1128/aac.02729-16 (2017).
- 621 10 Turton, J. F. *et al.* IncN3 and IncHI2 plasmids with an In1763 integron carrying bla (IMP-1) in
622 carbapenem-resistant Enterobacterales clinical isolates from the UK. *J Med Microbiol* **69**, 739-
623 747, doi:10.1099/jmm.0.001193 (2020).
- 624 11 England, P. H. Vol. 15 *Health Protection report* 1-14 (Assets publishing service UK government,
625 2021).
- 626 12 Poirel, L., Jayol, A. & Nordmann, P. Polymyxins: Antibacterial Activity, Susceptibility Testing,
627 and Resistance Mechanisms Encoded by Plasmids or Chromosomes. *Clinical microbiology*
628 *reviews* **30**, 557-596, doi:10.1128/cmr.00064-16 (2017).
- 629 13 Ling, Z. *et al.* Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9. *Journal of*
630 *Antimicrobial Chemotherapy* **75**, 3087-3095, doi:10.1093/jac/dkaa205 (2020).
- 631 14 Liu, Y. Y. *et al.* Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in
632 animals and human beings in China: a microbiological and molecular biological study. *Lancet*
633 *Infect Dis* **16**, 161-168, doi:10.1016/s1473-3099(15)00424-7 (2016).

- 634 15 Shen, Y. *et al.* Heterogeneous and Flexible Transmission of *mcr-1* in Hospital-Associated
635 *Escherichia coli*. *mBio* **9**, doi:10.1128/mBio.00943-18 (2018).
- 636 16 Carroll, L. M. *et al.* Identification of Novel Mobilized Colistin Resistance Gene *mcr-9* in a
637 Multidrug-Resistant, Colistin-Susceptible *Salmonella enterica* Serotype Typhimurium Isolate.
638 *mBio* **10**, doi:10.1128/mBio.00853-19 (2019).
- 639 17 Osei Sekyere, J., Maningi, N. E., Modipane, L. & Mbelle, N. M. Emergence of *mcr-9.1* in
640 Extended-Spectrum- β -Lactamase-Producing Clinical Enterobacteriaceae in Pretoria, South
641 Africa: Global Evolutionary Phylogenomics, Resistome, and Mobilome. *mSystems* **5** (2020).
- 642 18 Soliman, A. M. *et al.* Emergence of a Multidrug-Resistant *Enterobacter hormaechei* Clinical
643 Isolate from Egypt Co-Harboring *mcr-9* and *bla(VIM-4)*. *Microorganisms* **8**,
644 doi:10.3390/microorganisms8040595 (2020).
- 645 19 Macesic, N. *et al.* Silent spread of mobile colistin resistance gene *mcr-9.1* on IncHI2
646 'superplasmids' in clinical carbapenem-resistant Enterobacterales. *Clinical Microbiology and*
647 *Infection*, doi:<https://doi.org/10.1016/j.cmi.2021.04.020> (2021).
- 648 20 Hendrickx, A. P. A. *et al.* A genetic cluster of MDR *Enterobacter cloacae* complex ST78
649 harbouring a plasmid containing *blaVIM-1* and *mcr-9* in the Netherlands. *JAC-Antimicrobial*
650 *Resistance* **3**, doi:10.1093/jacamr/dlab046 (2021).
- 651 21 Li, Y. *et al.* Characterization of the global distribution and diversified plasmid reservoirs of the
652 colistin resistance gene *mcr-9*. *Scientific Reports* **10**, 8113, doi:10.1038/s41598-020-65106-w
653 (2020).
- 654 22 Meyers, L. Contact network epidemiology: Bond percolation applied to infectious disease
655 prediction and control. *Bulletin of the American Mathematical Society* **44**, 63-86 (2006).
- 656 23 Newman, M. E. J. The Structure and Function of Complex Networks. *SIAM Review* **45**, 167-256,
657 doi:10.1137/s003614450342480 (2003).
- 658 24 Pastor-Satorras, R., Castellano, C., Van Mieghem, P. & Vespignani, A. Epidemic processes in
659 complex networks. *Reviews of Modern Physics* **87**, 925-979, doi:10.1103/RevModPhys.87.925
660 (2015).
- 661 25 Klov Dahl, A. S. Social networks and the spread of infectious diseases: The AIDS example. *Social*
662 *Science & Medicine* **21**, 1203-1216, doi:[https://doi.org/10.1016/0277-9536\(85\)90269-2](https://doi.org/10.1016/0277-9536(85)90269-2)
663 (1985).
- 664 26 Keeling, M. J., Woolhouse, M. E. J., May, R. M., Davies, G. & Grenfell, B. T. Modelling
665 vaccination strategies against foot-and-mouth disease. *Nature* **421**, 136-142,
666 doi:10.1038/nature01343 (2003).
- 667 27 Salathé, M. *et al.* A high-resolution human contact network for infectious disease transmission.
668 *Proceedings of the National Academy of Sciences* **107**, 22020-22025,
669 doi:10.1073/pnas.1009094108 (2010).
- 670 28 Meyers, L. A., Newman, M. E. J. & Pourbohloul, B. Predicting epidemics on directed contact
671 networks. *Journal of Theoretical Biology* **240**, 400-418,
672 doi:<https://doi.org/10.1016/j.jtbi.2005.10.004> (2006).
- 673 29 Ancel Meyers, L., Newman, M. E. J., Martin, M. & Schrag, S. Applying network theory to
674 epidemics: control measures for *Mycoplasma pneumoniae* outbreaks. *Emerging infectious*
675 *diseases* **9**, 204-210, doi:10.3201/eid0902.020188 (2003).
- 676 30 Newman, M. E. J. Spread of epidemic disease on networks. *Physical Review E* **66**, 016128,
677 doi:10.1103/PhysRevE.66.016128 (2002).
- 678 31 Brockmann, D. & Helbing, D. The Hidden Geometry of Complex, Network-Driven Contagion
679 Phenomena. *Science* **342**, 1337, doi:10.1126/science.1245200 (2013).
- 680 32 Colizza, V., Barrat, A., Barthélemy, M. & Vespignani, A. The role of the airline transportation
681 network in the prediction and predictability of global epidemics. *Proceedings of the National*
682 *Academy of Sciences* **103**, 2015-2020, doi:10.1073/pnas.0510525103 (2006).

- 683 33 Kwong, J. C. *et al.* Translating genomics into practice for real-time surveillance and response
684 to carbapenemase-producing Enterobacteriaceae: evidence from a complex multi-
685 institutional KPC outbreak. *PeerJ* **6**, e4210-e4210, doi:10.7717/peerj.4210 (2018).
- 686 34 Gouliouris, T. *et al.* Quantifying acquisition and transmission of Enterococcus faecium using
687 genomic surveillance. *Nat Microbiol*, doi:10.1038/s41564-020-00806-7 (2020).
- 688 35 Otter, J. A. *et al.* Detecting carbapenemase-producing Enterobacteriales (CPE): an evaluation
689 of an enhanced CPE infection control and screening programme in acute care. *Journal of*
690 *Antimicrobial Chemotherapy* **75**, 2670-2676, doi:10.1093/jac/dkaa192 (2020).
- 691 36 Rodriguez-Manzano, J. *et al.* Rapid Detection of Mobilized Colistin Resistance using a Nucleic
692 Acid Based Lab-on-a-Chip Diagnostic System. *Scientific reports* **10**, 8448, doi:10.1038/s41598-
693 020-64612-1 (2020).
- 694 37 Furniss, R. C. D. *et al.* Detection of Colistin Resistance in *Escherichia coli* by Use of the MALDI Biotyper Sirius
695 Mass Spectrometry System. *Journal of clinical microbiology* **57**, e01427-01419,
696 doi:10.1128/jcm.01427-19 (2019).
- 698 38 Landman, D., Salamera, J. & Quale, J. Irreproducible and uninterpretable Polymyxin B MICs for
699 Enterobacter cloacae and Enterobacter aerogenes. *Journal of clinical microbiology* **51**, 4106-
700 4111, doi:10.1128/jcm.02129-13 (2013).
- 701 39 Fournier, S. *et al.* Efficiency of different control measures for preventing carbapenemase-
702 producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-
703 year prospective study in a French multihospital institution, January 2010 to December 2015.
704 *Euro Surveill* **23**, 17-00078, doi:10.2807/1560-7917.ES.2018.23.8.17-00078 (2018).
- 705 40 Haenni, M. *et al.* Co-occurrence of extended spectrum β lactamase and MCR-1 encoding genes
706 on plasmids. *Lancet Infect Dis* **16**, 281-282, doi:10.1016/s1473-3099(16)00007-4 (2016).
- 707 41 Yin, W. *et al.* Novel Plasmid-Mediated Colistin Resistance Gene mcr-3 in Escherichia coli. *MBio*
708 **8**, doi:10.1128/mBio.00543-17 (2017).
- 709 42 Kieffer, N. *et al.* mcr-9, an Inducible Gene Encoding an Acquired Phosphoethanolamine
710 Transferase in Escherichia coli, and Its Origin. *Antimicrobial agents and chemotherapy* **63**,
711 doi:10.1128/aac.00965-19 (2019).
- 712 43 Otter, J. A. *et al.* Emergence and clonal spread of colistin resistance due to multiple mutational
713 mechanisms in carbapenemase-producing Klebsiella pneumoniae in London. *Scientific reports*
714 **7**, 12711, doi:10.1038/s41598-017-12637-4 (2017).
- 715 44 Otter, J. A., Mutters, N. T., Tacconelli, E., Gikas, A. & Holmes, A. H. Controversies in guidelines
716 for the control of multidrug-resistant Gram-negative bacteria in EU countries. *Clinical*
717 *microbiology and infection : the official publication of the European Society of Clinical*
718 *Microbiology and Infectious Diseases* **21**, 1057-1066, doi:10.1016/j.cmi.2015.09.021 (2015).
- 719 45 Jamal, A. J. *et al.* Infection prevention and control practices related to carbapenemase-
720 producing Enterobacteriaceae (CPE) in acute-care hospitals in Ontario, Canada. *Infection*
721 *Control & Hospital Epidemiology* **40**, 1006-1012, doi:10.1017/ice.2019.173 (2019).
- 722 46 Harris, A. D., McGregor, J. C. & Furuno, J. P. What Infection Control Interventions Should Be
723 Undertaken to Control Multidrug-Resistant Gram-Negative Bacteria? *Clinical Infectious*
724 *Diseases* **43**, S57-S61, doi:10.1086/504479 (2006).
- 725 47 Doron, S. & Davidson, L. E. Antimicrobial stewardship. *Mayo Clin Proc* **86**, 1113-1123,
726 doi:10.4065/mcp.2011.0358 (2011).
- 727 48 Amoureux, L. *et al.* Nosocomial Infections with IMP-19-Producing Pseudomonas aeruginosa
728 Linked to Contaminated Sinks, France. *Emerging infectious diseases* **23**, 304-307,
729 doi:10.3201/eid2302.160649 (2017).
- 730 49 Mollenkopf, D. F. *et al.* Carbapenemase-Producing Enterobacteriaceae Recovered from the
731 Environment of a Swine Farrow-to-Finish Operation in the United States. *Antimicrobial agents*
732 *and chemotherapy* **61**, e01298-01216, doi:10.1128/AAC.01298-16 (2017).

- 733 50 Heireman, L. *et al.* Toilet drain water as a potential source of hospital room-to-room
734 transmission of carbapenemase-producing *Klebsiella pneumoniae*. *The Journal of hospital*
735 *infection* **106**, 232-239, doi:10.1016/j.jhin.2020.07.017 (2020).
- 736 51 Regev-Yochay, G. *et al.* Sink traps as the source of transmission of OXA-48-producing *Serratia*
737 *marcescens* in an intensive care unit. *Infect Control Hosp Epidemiol* **39**, 1307-1315,
738 doi:10.1017/ice.2018.235 (2018).
- 739 52 EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1.
740 *European Committee on Antimicrobial Susceptibility Testing* (2017).
- 741 53 Rodriguez-Manzano, J. *et al.* Rapid Detection of Mobilized Colistin Resistance using a Nucleic
742 Acid Based Lab-on-a-Chip Diagnostic System. *Sci Rep* **10**, 8448, doi:10.1038/s41598-020-
743 64612-1 (2020).
- 744 54 Andrews, S. FASTQC. A quality control tool for high throughput sequence data. (2010).
- 745 55 Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence
746 data. *Bioinformatics (Oxford, England)* **30**, 2114-2120, doi:10.1093/bioinformatics/btu170
747 (2014).
- 748 56 Bankevich, A. *et al.* SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-
749 Cell Sequencing. *Journal of Computational Biology* **19**, 455-477, doi:10.1089/cmb.2012.0021
750 (2012).
- 751 57 Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**, 2068-2069,
752 doi:10.1093/bioinformatics/btu153 (2014).
- 753 58 Larsen, M. V. *et al.* Benchmarking of methods for genomic taxonomy. *Journal of clinical*
754 *microbiology* **52**, 1529-1539, doi:10.1128/jcm.02981-13 (2014).
- 755 59 Larsen, M. V. *et al.* Multilocus sequence typing of total-genome-sequenced bacteria. *Journal*
756 *of clinical microbiology* **50**, 1355-1361, doi:10.1128/jcm.06094-11 (2012).
- 757 60 Jolley, K. A., Bray, J. E. & Maiden, M. C. J. Open-access bacterial population genomics: BIGSdb
758 software, the PubMLST.org website and their applications. *Wellcome Open Res* **3**, 124,
759 doi:10.12688/wellcomeopenres.14826.1 (2018).
- 760 61 Zankari, E. *et al.* Identification of acquired antimicrobial resistance genes. *J Antimicrob*
761 *Chemother* **67**, 2640-2644, doi:10.1093/jac/dks261 (2012).
- 762 62 Carattoli, A. *et al.* In silico detection and typing of plasmids using PlasmidFinder and plasmid
763 multilocus sequence typing. *Antimicrobial agents and chemotherapy* **58**, 3895-3903,
764 doi:10.1128/aac.02412-14 (2014).
- 765 63 Jain, C., Rodriguez, R. L., Phillippy, A. M., Konstantinidis, K. T. & Aluru, S. High throughput ANI
766 analysis of 90K prokaryotic genomes reveals clear species boundaries. *Nature*
767 *communications* **9**, 5114, doi:10.1038/s41467-018-07641-9 (2018).
- 768 64 Gilmour, M. W., Thomson, N. R., Sanders, M., Parkhill, J. & Taylor, D. E. The complete
769 nucleotide sequence of the resistance plasmid R478: defining the backbone components of
770 incompatibility group H conjugative plasmids through comparative genomics. *Plasmid* **52**,
771 182-202, doi:<https://doi.org/10.1016/j.plasmid.2004.06.006> (2004).
- 772 65 Kurtz, S. *et al.* Versatile and open software for comparing large genomes. *Genome Biology* **5**,
773 R12, doi:10.1186/gb-2004-5-2-r12 (2004).
- 774 66 Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: A Fast and Effective
775 Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Molecular Biology and*
776 *Evolution* **32**, 268-274, doi:10.1093/molbev/msu300 (2014).
- 777 67 Didelot, X. & Wilson, D. J. ClonalFrameML: efficient inference of recombination in whole
778 bacterial genomes. *PLoS computational biology* **11**, e1004041,
779 doi:10.1371/journal.pcbi.1004041 (2015).
- 780 68 Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display
781 and annotation. *Bioinformatics (Oxford, England)* **23**, 127-128,
782 doi:10.1093/bioinformatics/btl529 (2006).

783 69 Galili, T. dendextend: an R package for visualizing, adjusting and comparing trees of
784 hierarchical clustering. *Bioinformatics (Oxford, England)* **31**, 3718-3720,
785 doi:10.1093/bioinformatics/btv428 (2015).
786 70 Pons, P. & Latapy, M. 284-293 (Springer Berlin Heidelberg).
787 71 Gómez, S., Arenas, A., Borge-Holthoefer, J., Meloni, S. & Moreno, Y. Discrete-time Markov
788 chain approach to contact-based disease spreading in complex networks. *EPL (Europhysics*
789 *Letters)* **89**, 38009, doi:10.1209/0295-5075/89/38009 (2010).
790 72 Holme, P. & Saramäki, J. Temporal networks. *Physics Reports* **519**, 97-125,
791 doi:<https://doi.org/10.1016/j.physrep.2012.03.001> (2012).
792 73 Senanayake, U., Piraveenan, M. & Zomaya, A. The Pagerank-Index: Going beyond Citation
793 Counts in Quantifying Scientific Impact of Researchers. *PLoS one* **10**, e0134794-e0134794,
794 doi:10.1371/journal.pone.0134794 (2015).
795 74 Page, L., Brin, Sergey, Motwani, Rajeev, Winograd, Terry. The PageRank Citation Ranking:
796 Bringing Order to the Web. (Stanford University, Stanford InfoLab Publication Server, 1999).
797 75 Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular
798 interaction networks. *Genome Res* **13**, 2498-2504, doi:10.1101/gr.1239303 (2003).
799
800